0001209191-20-003219.txt : 20200113
0001209191-20-003219.hdr.sgml : 20200113
20200113184829
ACCESSION NUMBER: 0001209191-20-003219
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200109
FILED AS OF DATE: 20200113
DATE AS OF CHANGE: 20200113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Opaleye, L.P.
CENTRAL INDEX KEY: 0001391634
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 20524673
BUSINESS ADDRESS:
STREET 1: 9B RUSSELL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 01240
BUSINESS PHONE: 617-229-5085
MAIL ADDRESS:
STREET 1: 9B RUSSELL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 01240
FORMER NAME:
FORMER CONFORMED NAME: RRC BIO FUND, L. P.
DATE OF NAME CHANGE: 20090810
FORMER NAME:
FORMER CONFORMED NAME: RRC BIO FUND L P
DATE OF NAME CHANGE: 20070228
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ArTara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 LITTLE WEST 12TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: 646-844-0337
MAIL ADDRESS:
STREET 1: 1 LITTLE WEST 12TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10014
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC
DATE OF NAME CHANGE: 20060420
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-09
0
0001359931
ArTara Therapeutics, Inc.
TARA
0001391634
Opaleye, L.P.
13 GYPSY TRAIL
WESTON
MA
02493
0
0
1
0
Common Stock
2020-01-09
4
A
0
777635
A
782238
D
Common Stock
2020-01-09
4
A
0
1426234
7.01
A
2208472
D
On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly-owned subsidiary of the Issuer.
These shares were received in exchange for: i) 571,428 shares of ArTara Sub common stock; and ii) 3,505,174 shares of ArTara Sub exchangeable common stock, in connection with the merger.
/s/ James Silverman, Managing Member of Opaleye GP LLC, General Partner of Reporting Person
2020-01-13